Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1994 1
2004 6
2008 1
2009 2
2010 3
2011 6
2012 4
2013 7
2014 10
2015 12
2016 20
2017 19
2018 17
2019 22
2020 25
2021 23
2022 25
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29084827

171 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT.
Wieser G, Popp I, Christian Rischke H, Drendel V, Grosu AL, Bartholomä M, Weber WA, Mansi R, Wetterauer U, Schultze-Seemann W, Meyer PT, Jilg CA. Wieser G, et al. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1463-1472. doi: 10.1007/s00259-017-3702-8. Epub 2017 Apr 18. Eur J Nucl Med Mol Imaging. 2017. PMID: 28417160
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA. Touijer KA, et al. Eur Urol Oncol. 2019 Mar;2(2):166-173. doi: 10.1016/j.euo.2018.08.011. Epub 2018 Sep 22. Eur Urol Oncol. 2019. PMID: 31017093 Free PMC article. Clinical Trial.
Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, Iagaru A. Duan H, et al. J Nucl Med. 2022 Dec;63(12):1829-1835. doi: 10.2967/jnumed.122.263971. Epub 2022 May 12. J Nucl Med. 2022. PMID: 35552245 Free article.
Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study.
Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, Bladou F, Bénard A, Hindié E, Gallerande HC, Morgat C. Schollhammer R, et al. J Nucl Med. 2023 Mar;64(3):379-385. doi: 10.2967/jnumed.122.263889. Epub 2022 Sep 2. J Nucl Med. 2023. PMID: 36215569 Free PMC article. Clinical Trial.
Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
Beheshti M, Taimen P, Kemppainen J, Jambor I, Müller A, Loidl W, Kähkönen E, Käkelä M, Berndt M, Stephens AW, Minn H, Langsteger W. Beheshti M, et al. Eur Radiol. 2023 Jan;33(1):472-482. doi: 10.1007/s00330-022-08982-2. Epub 2022 Jul 21. Eur Radiol. 2023. PMID: 35864350 Free PMC article. Clinical Trial.
171 results